Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 20 | 2024 | 76 | 4.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 18 | 2024 | 755 | 3.770 |
Why?
|
| Prediabetic State | 7 | 2024 | 56 | 3.540 |
Why?
|
| Postmenopause | 25 | 2025 | 243 | 2.840 |
Why?
|
| Weight Loss | 8 | 2025 | 305 | 2.080 |
Why?
|
| Women's Health | 20 | 2023 | 202 | 1.840 |
Why?
|
| Humans | 95 | 2025 | 17822 | 1.730 |
Why?
|
| Female | 81 | 2025 | 12780 | 1.640 |
Why?
|
| Obesity | 12 | 2023 | 842 | 1.590 |
Why?
|
| Cholecalciferol | 9 | 2019 | 15 | 1.520 |
Why?
|
| Aged | 60 | 2025 | 6173 | 1.520 |
Why?
|
| Accidental Falls | 4 | 2015 | 42 | 1.470 |
Why?
|
| Menopause | 6 | 2020 | 69 | 1.400 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 272 | 1.400 |
Why?
|
| Fractures, Bone | 7 | 2022 | 95 | 1.330 |
Why?
|
| Blood Glucose | 6 | 2024 | 349 | 1.320 |
Why?
|
| Vitamins | 7 | 2024 | 64 | 1.290 |
Why?
|
| Dietary Supplements | 13 | 2020 | 87 | 1.270 |
Why?
|
| Risk Factors | 41 | 2025 | 3362 | 1.240 |
Why?
|
| Mass Screening | 4 | 2022 | 678 | 1.220 |
Why?
|
| Vitamin D Deficiency | 4 | 2015 | 21 | 1.180 |
Why?
|
| Calcium Carbonate | 6 | 2019 | 9 | 1.110 |
Why?
|
| Middle Aged | 49 | 2025 | 8020 | 1.100 |
Why?
|
| Prenatal Care | 2 | 2020 | 130 | 1.100 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2024 | 39 | 1.080 |
Why?
|
| Cognition | 6 | 2013 | 83 | 1.050 |
Why?
|
| Osteoporotic Fractures | 6 | 2017 | 41 | 0.990 |
Why?
|
| Exercise Therapy | 3 | 2015 | 71 | 0.970 |
Why?
|
| Behavior Therapy | 4 | 2021 | 146 | 0.970 |
Why?
|
| Prospective Studies | 24 | 2025 | 1286 | 0.960 |
Why?
|
| Calcium, Dietary | 5 | 2017 | 27 | 0.960 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 599 | 0.920 |
Why?
|
| Metformin | 2 | 2022 | 58 | 0.910 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2017 | 99 | 0.910 |
Why?
|
| Aging | 4 | 2015 | 163 | 0.850 |
Why?
|
| Hip Fractures | 6 | 2016 | 70 | 0.830 |
Why?
|
| Testosterone | 3 | 2014 | 23 | 0.830 |
Why?
|
| Estradiol | 4 | 2014 | 24 | 0.820 |
Why?
|
| Calcium | 6 | 2020 | 35 | 0.800 |
Why?
|
| Hot Flashes | 6 | 2020 | 39 | 0.790 |
Why?
|
| Estrogens | 5 | 2022 | 61 | 0.790 |
Why?
|
| Dementia | 3 | 2020 | 112 | 0.770 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 216 | 0.750 |
Why?
|
| Weight Gain | 6 | 2020 | 173 | 0.740 |
Why?
|
| Health Behavior | 5 | 2021 | 360 | 0.740 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 18 | 0.710 |
Why?
|
| Aged, 80 and over | 17 | 2019 | 1931 | 0.700 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2016 | 23 | 0.660 |
Why?
|
| Incidence | 14 | 2019 | 1269 | 0.650 |
Why?
|
| Male | 18 | 2024 | 10145 | 0.640 |
Why?
|
| Adult | 20 | 2024 | 7708 | 0.640 |
Why?
|
| Preconception Care | 2 | 2016 | 44 | 0.630 |
Why?
|
| Cognitive Dysfunction | 2 | 2016 | 50 | 0.630 |
Why?
|
| Breast Density | 4 | 2022 | 31 | 0.630 |
Why?
|
| Obesity Management | 1 | 2018 | 4 | 0.620 |
Why?
|
| Body Mass Index | 16 | 2025 | 967 | 0.620 |
Why?
|
| United States | 23 | 2025 | 4007 | 0.590 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 201 | 0.590 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2016 | 27 | 0.580 |
Why?
|
| Cohort Studies | 16 | 2020 | 2590 | 0.580 |
Why?
|
| Primary Health Care | 2 | 2015 | 770 | 0.570 |
Why?
|
| Demography | 1 | 2017 | 101 | 0.560 |
Why?
|
| Femoral Fractures | 1 | 2017 | 23 | 0.560 |
Why?
|
| Follow-Up Studies | 15 | 2023 | 1219 | 0.560 |
Why?
|
| Menstruation | 1 | 2017 | 7 | 0.550 |
Why?
|
| Sleep | 3 | 2024 | 58 | 0.550 |
Why?
|
| Reproductive History | 1 | 2017 | 17 | 0.550 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 57 | 0.540 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 1335 | 0.530 |
Why?
|
| Breast | 4 | 2019 | 85 | 0.520 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 52 | 0.500 |
Why?
|
| Residence Characteristics | 2 | 2017 | 251 | 0.500 |
Why?
|
| Treatment Outcome | 10 | 2021 | 1265 | 0.490 |
Why?
|
| Pregnancy | 8 | 2024 | 1529 | 0.480 |
Why?
|
| Diet | 4 | 2021 | 366 | 0.480 |
Why?
|
| Time Factors | 9 | 2019 | 1097 | 0.460 |
Why?
|
| Body Composition | 3 | 2023 | 90 | 0.450 |
Why?
|
| Diphosphonates | 1 | 2014 | 65 | 0.440 |
Why?
|
| Double-Blind Method | 9 | 2019 | 160 | 0.440 |
Why?
|
| Macular Degeneration | 4 | 2015 | 20 | 0.430 |
Why?
|
| Drug Compounding | 1 | 2013 | 4 | 0.430 |
Why?
|
| Nonprescription Drugs | 1 | 2013 | 6 | 0.430 |
Why?
|
| Bone Density | 6 | 2019 | 97 | 0.430 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 957 | 0.420 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 711 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 329 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 379 | 0.350 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 1323 | 0.350 |
Why?
|
| Spinal Fractures | 3 | 2016 | 12 | 0.350 |
Why?
|
| Mortality | 2 | 2025 | 118 | 0.340 |
Why?
|
| Health Status Disparities | 1 | 2011 | 147 | 0.340 |
Why?
|
| Overweight | 4 | 2016 | 270 | 0.330 |
Why?
|
| Adolescent | 8 | 2022 | 3690 | 0.330 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2019 | 43 | 0.320 |
Why?
|
| Preventive Health Services | 2 | 2022 | 160 | 0.320 |
Why?
|
| Body Weight | 3 | 2020 | 224 | 0.310 |
Why?
|
| Menarche | 2 | 2019 | 28 | 0.300 |
Why?
|
| Sweating | 3 | 2017 | 9 | 0.290 |
Why?
|
| Waist Circumference | 2 | 2025 | 39 | 0.280 |
Why?
|
| Exercise | 3 | 2021 | 495 | 0.280 |
Why?
|
| Child | 7 | 2023 | 2497 | 0.270 |
Why?
|
| Neoplasms | 4 | 2016 | 445 | 0.270 |
Why?
|
| Life Style | 3 | 2015 | 334 | 0.270 |
Why?
|
| Fetal Macrosomia | 3 | 2021 | 26 | 0.260 |
Why?
|
| Age Factors | 5 | 2016 | 923 | 0.250 |
Why?
|
| Adiposity | 2 | 2023 | 66 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 107 | 0.250 |
Why?
|
| Risk Assessment | 5 | 2017 | 1103 | 0.240 |
Why?
|
| Self Report | 5 | 2019 | 253 | 0.240 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 147 | 0.240 |
Why?
|
| Emotions | 2 | 2015 | 34 | 0.240 |
Why?
|
| Fatigue | 2 | 2015 | 34 | 0.240 |
Why?
|
| Sleep Wake Disorders | 2 | 2015 | 37 | 0.230 |
Why?
|
| Sex Characteristics | 1 | 2024 | 69 | 0.230 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2024 | 46 | 0.230 |
Why?
|
| Diet, Reducing | 3 | 2015 | 25 | 0.230 |
Why?
|
| Neuropsychological Tests | 3 | 2016 | 41 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2017 | 2467 | 0.220 |
Why?
|
| Insulin Resistance | 1 | 2024 | 137 | 0.220 |
Why?
|
| Carotenoids | 2 | 2014 | 29 | 0.220 |
Why?
|
| Patient Compliance | 2 | 2016 | 301 | 0.220 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 213 | 0.210 |
Why?
|
| Body Size | 2 | 2020 | 31 | 0.210 |
Why?
|
| Sex Factors | 1 | 2024 | 644 | 0.200 |
Why?
|
| Young Adult | 5 | 2022 | 2464 | 0.200 |
Why?
|
| Osteoporosis | 2 | 2014 | 78 | 0.200 |
Why?
|
| Advisory Committees | 1 | 2022 | 113 | 0.190 |
Why?
|
| Premature Birth | 1 | 2023 | 137 | 0.190 |
Why?
|
| Geriatric Assessment | 2 | 2012 | 40 | 0.180 |
Why?
|
| Odds Ratio | 8 | 2017 | 673 | 0.180 |
Why?
|
| Pregnancy Trimesters | 1 | 2020 | 30 | 0.170 |
Why?
|
| Glycemic Load | 1 | 2020 | 1 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 487 | 0.170 |
Why?
|
| Glycemic Index | 1 | 2020 | 20 | 0.170 |
Why?
|
| Sexual Maturation | 1 | 2019 | 8 | 0.170 |
Why?
|
| Anthropometry | 1 | 2020 | 66 | 0.170 |
Why?
|
| Adipose Tissue | 2 | 2018 | 64 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 100 | 0.170 |
Why?
|
| Contraceptives, Oral | 1 | 1999 | 26 | 0.170 |
Why?
|
| Hispanic Americans | 3 | 2021 | 404 | 0.160 |
Why?
|
| Counseling | 1 | 2021 | 189 | 0.160 |
Why?
|
| Parity | 1 | 2019 | 74 | 0.160 |
Why?
|
| Puberty | 1 | 2019 | 58 | 0.160 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 158 | 0.160 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 119 | 0.160 |
Why?
|
| Logistic Models | 3 | 2016 | 928 | 0.160 |
Why?
|
| Dietary Fats | 2 | 2016 | 91 | 0.150 |
Why?
|
| Bias | 1 | 2018 | 103 | 0.150 |
Why?
|
| Health Promotion | 1 | 2021 | 281 | 0.150 |
Why?
|
| European Continental Ancestry Group | 3 | 2017 | 529 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2019 | 137 | 0.140 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 15 | 0.140 |
Why?
|
| Feeding Behavior | 2 | 2016 | 166 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2017 | 1 | 0.140 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 12 | 0.140 |
Why?
|
| Hysterectomy | 1 | 2017 | 29 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 42 | 0.140 |
Why?
|
| Biomarkers | 2 | 2015 | 310 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 35 | 0.140 |
Why?
|
| Calcifediol | 2 | 2014 | 3 | 0.130 |
Why?
|
| Body Height | 2 | 2018 | 62 | 0.130 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2016 | 2 | 0.130 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 7 | 0.130 |
Why?
|
| Reproduction | 1 | 2016 | 13 | 0.130 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cause of Death | 2 | 2019 | 181 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2015 | 8 | 0.130 |
Why?
|
| Complement Factor I | 1 | 2015 | 1 | 0.130 |
Why?
|
| Age of Onset | 1 | 2015 | 79 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 630 | 0.120 |
Why?
|
| Institutionalization | 1 | 2015 | 1 | 0.120 |
Why?
|
| Homes for the Aged | 1 | 2015 | 5 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 144 | 0.120 |
Why?
|
| Vasomotor System | 1 | 2014 | 5 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2020 | 698 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 29 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 134 | 0.120 |
Why?
|
| African Americans | 2 | 2017 | 472 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 7 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 720 | 0.120 |
Why?
|
| Insulin | 1 | 2015 | 213 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 67 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 54 | 0.110 |
Why?
|
| Oregon | 1 | 2014 | 181 | 0.110 |
Why?
|
| Risk | 2 | 2009 | 518 | 0.110 |
Why?
|
| Hand Strength | 1 | 2013 | 10 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 63 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2015 | 165 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 172 | 0.110 |
Why?
|
| Memory | 1 | 2013 | 12 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 170 | 0.110 |
Why?
|
| Washington | 1 | 2014 | 383 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2012 | 31 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 181 | 0.110 |
Why?
|
| Retinal Pigments | 1 | 2013 | 3 | 0.110 |
Why?
|
| Asian Americans | 1 | 2014 | 176 | 0.110 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 2 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.100 |
Why?
|
| Walking | 1 | 2013 | 86 | 0.100 |
Why?
|
| Research Design | 2 | 2011 | 376 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 417 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Thyroxine | 1 | 2012 | 6 | 0.100 |
Why?
|
| Thyroid Gland | 1 | 2012 | 6 | 0.100 |
Why?
|
| Thyrotropin | 1 | 2012 | 7 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2023 | 858 | 0.100 |
Why?
|
| Lactones | 1 | 2011 | 11 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 246 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2011 | 10 | 0.100 |
Why?
|
| World Health Organization | 1 | 2011 | 14 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2011 | 22 | 0.100 |
Why?
|
| Models, Biological | 1 | 2011 | 30 | 0.090 |
Why?
|
| Prevalence | 4 | 2016 | 888 | 0.090 |
Why?
|
| Absorptiometry, Photon | 2 | 2023 | 50 | 0.090 |
Why?
|
| Diabetes, Gestational | 2 | 2021 | 346 | 0.090 |
Why?
|
| Melanoma | 1 | 2011 | 35 | 0.090 |
Why?
|
| Survival Rate | 1 | 2011 | 260 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 93 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 156 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 57 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 186 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 115 | 0.080 |
Why?
|
| Mammography | 2 | 2022 | 169 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 85 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1120 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 506 | 0.070 |
Why?
|
| Sleep Deprivation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Stroke | 2 | 2019 | 315 | 0.070 |
Why?
|
| Phenotype | 2 | 2019 | 151 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 615 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 129 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 455 | 0.060 |
Why?
|
| Genotype | 2 | 2015 | 227 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 569 | 0.060 |
Why?
|
| Prognosis | 2 | 2011 | 609 | 0.060 |
Why?
|
| Maternal Age | 1 | 2021 | 77 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2021 | 32 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2001 | 72 | 0.040 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 46 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2021 | 64 | 0.040 |
Why?
|
| Dementia, Vascular | 1 | 2020 | 5 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 50 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2020 | 64 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 111 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 30 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 21 | 0.040 |
Why?
|
| Hip Joint | 1 | 2019 | 3 | 0.040 |
Why?
|
| Femur Neck | 1 | 2019 | 5 | 0.040 |
Why?
|
| Actigraphy | 1 | 2019 | 16 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 35 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 58 | 0.040 |
Why?
|
| Biopsy | 1 | 1999 | 75 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 79 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 1999 | 330 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 238 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 6 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 6 | 0.040 |
Why?
|
| Metabolomics | 1 | 2017 | 8 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 3 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 32 | 0.030 |
Why?
|
| Intention | 1 | 2017 | 28 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 55 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 50 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 17 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 30 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 45 | 0.030 |
Why?
|
| Complement Factor B | 1 | 2015 | 1 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Complement Factor H | 1 | 2015 | 2 | 0.030 |
Why?
|
| Proteins | 1 | 2015 | 16 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 249 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2015 | 5 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 154 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 30 | 0.030 |
Why?
|
| Fetal Development | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cholesterol | 1 | 2014 | 106 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 81 | 0.030 |
Why?
|
| beta-Carotene 15,15'-Monooxygenase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2013 | 1 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 303 | 0.030 |
Why?
|
| Urinary Calculi | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Sunlight | 1 | 2012 | 13 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 33 | 0.030 |
Why?
|
| Edible Grain | 1 | 2012 | 14 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 597 | 0.030 |
Why?
|
| Seasons | 1 | 2012 | 105 | 0.030 |
Why?
|
| Fruit | 1 | 2012 | 79 | 0.030 |
Why?
|
| Vegetables | 1 | 2012 | 87 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 2 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2011 | 10 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 16 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2015 | 485 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2011 | 86 | 0.020 |
Why?
|
| Zeaxanthins | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tocopherols | 1 | 2010 | 5 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2010 | 6 | 0.020 |
Why?
|
| Lutein | 1 | 2010 | 7 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 10 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 59 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 212 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 1 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 302 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 262 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 178 | 0.020 |
Why?
|
Concepts
(311)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(9)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->